The rise of the GLP-1 patch directly addresses some of the most common hurdles we've encountered over the years
3,4 This receptor and its agonists hold significant therapeutic potential, reshaping the treatment approaches for multiple diseases, including diabetes, cardiovascular disorders, and neurodegenerative diseases
In pancreatic tissue, GLP-1 receptor agonists enhance glucose-dependent insulin secretion and suppress inappropriate glucagon release, thereby improving glycemic control without significantly increasing hypoglycemia risk
Confidence that feels natural
Pentadecapeptide BPC-157: from GI tract to whole body healing Related research, protocols, and guides Explore the available research context, protocol variants or comparisons, and practical guides
N Engl J Med 2023;389:51426.ArticlePubMed 66